Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade...
High-grade GliomaOligodendroglioma2 moreThis is a phase 1 open-label, multicenter study to investigate tolerability, safety and PK properties of oral OKN-007 in patients with recurrent high-grade glioma.
A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed...
Anaplastic OligoastrocytomaGlioblastomaThis study was to explore the effectiveness and safety of early TMZ chemotherapy between surgery and chemoradiotherapy plus the standard concomitant radiochemotherapy regimen.
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
GlioblastomaIDH-wildtype4 moreThe purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
GliomaGlioma7 moreThis single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
GlioblastomaThis phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM). The researchers want to learn whether the shorter course treatment is non-inferior (not worse than the standard of care), for patients with GBM. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Short course radiotherapy delivers higher doses of radiation over a shorter period of time and may kill more tumor cells and have fewer side effects.
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
High Grade Astrocytic TumorRecurrent Glioblastoma2 moreThis phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving efineptakin alfa and pembrolizumab may kill more tumor cells in patients with recurrent glioblastoma.
Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard...
Glioblastom WHO Grade 4Locoregional, intracavitary radioimmunotherapy (iRIT) with a newly developed radioimmunoconjugate (Lu-177 labeled 6A10-Fab-fragments) will be used to prevent or postpone tumour recurrence in patients with GBM following standard therapy . Following study objectives will be analyzed: Determining the Maximum Tolerated Dose (MTD) Determining safety by assessing all new neurological, hematological and other AEs CTC grade 2 or higher Determining absorbed dose to the 2 cm shell of the resection cavity (based on a series of SPECT/CTs of the head 2h,24h,48h, 72h p.i. and on day 5-7) Determining absorbed dose values for the kidneys, the liver, the active marrow (based on a series of SPECT/CTs of the abdomen 2h,24h,48h, 72h p.i. and on day 5-7) Determining 24 weeks Progression-Free-Survival (PFS), defined from the day of inclusion
PARP Inhibition for Gliomas (PI-4G or π4g)
Recurrent GlioblastomaRecurrent Astrocytoma2 moreThe purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients...
Glioblastoma MultiformeRecurrent GlioblastomaThe FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Glioblastoma MultiformeTo evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801. To evaluate the antitumor activity of ERAS-801. To evaluate the PK profile of ERAS-801.